动物实验,沃替西汀 z-bo 2020-08-28 752

　　Objective: To study the effect of a new antidepressant vortioxetine on the cyclic adenosine monophosphate/cyclic adenosine monophosphate response element binding protein/brain-derived neurotrophic factor (cAMP/CREBβ/BDNF) signaling pathway.

　　Method: Kunming mice were randomly divided into a control group and a chronic unpredictable mild stress (CUMS) model, and the sugar water preference test was used to study whether the model was successfully established. After modeling, the mice in the CUMS group were randomly divided into model group, fluoxetine group and vortioxetine group. Tail suspension test, forced swimming test and field test are used to study the antidepressant effect of vortioxetine on depressed mice. ELISA kit is used to detect cAMP content in mouse hippocampus. Western blotting was used to detect the protein expression of phosphorylated CREB (pCREB) and BDNF in the mouse hippocampus.

　　Result: Bortioxetine can significantly reduce the immobility time of mice in the tail suspension and forced swimming test (P0.05), while Baltioxetine can improve the depression-like behavior of mice with depression. Enzyme-linked immunosorbent assay (ELISA) results show that forltidine can significantly increase the cAMP content in the hippocampus of mice (P\u003c0.01). Western blot results showed that vortioxetine can enhance the expression of pCREB and BDNF protein (P\u003c0.01).

　　Conclusion: The antidepressant mechanism of vortioxetine may be related to the cAMP /CREBβ/BDNF signaling pathway.